Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) on Thursday released topline results from an interim analysis of a Phase 3 trial indicating that the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, is more effective in preventing HIV infection in women compared to its existing daily pill, Truvada.
Gilead said that there were zero cases of HIV infection among women who were treated with lenacapavir. More detailed data will be presented at a later date.
Truvada, a combination of tenofovir and emtricitabine, can treat HIV and is also used in a prevention regimen known as pre-exposure prophylaxis (PrEP).
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Lilly's Jaypirca delivers breakthrough results in front-line CLL trial